Clinical trials: Bladder Cancers
Non-muscular Invasive Bladder Cancer
BCG for Therapeutic Use Phase I Clinical Trial
This clinical study adopted a single-arm, open, single-centertrial design. The purpose of this study was to evaluate the safety and tolerability, PK characteristics, shedding and immune response characteristics of BCG for…
- Trial name
- NCT06100653
- Testing
- BCG for therapeutic use
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
Recurrent or Metastatic Bladder Cancer
An Open, Dose-escalation Clinical Study of Chimeric Exosomal Tumor Vaccines for Recurrent or Metastatic Bladder Cancer
1. Based on the applicant's previous work and combined with the clinical medical resources of our unit, tumor cells were isolated from the lesion site of cancer patients, dendritic cells or macrophages were isolated from…
- Trial name
- NCT05559177
- Testing
- Chimeric exosomal tumor vaccines
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Shanghai Pudong Hospital
NMIBC, TURBT
Anesthesia Modality and Oncologic Outcomes in High-Risk NMIBC: A Randomized Trial
To demonstrate the superior efficacy of spinal anesthesia (SA) versus general anesthesia (GA) according to the delay of time to recurrence in high-risk NMIBC patients up to Week 104 after TURBT.
- Conditions
- NMIBC, TURBT, Bladder (Urothelial, Transitional Cell) Cancer, Bladder Cancer Recurrence
- Trial name
- NCT06982690
- Testing
- Spinal Anesthesia, General Anesthesia
- Where
- Taiwan
- Volunteers
- 370 people
- Sponsor
- National Taiwan University Hospital
Various Advanced Cancer
A Study of Nivolumab in Participants With Metastatic or Unresectable Bladder Cancer
The purpose the study is to measure the effect of nivolumab (BMS-936558) in reducing tumor size in subjects with metastatic or unresectable bladder cancer.
- Trial name
- NCT02387996
- Testing
- Nivolumab
- Where
- 67 sites in United States, Australia and 9 more
- Volunteers
- 270 people
- Sponsor
- Bristol-Myers Squibb
Hematuria, Dysuria
Efficacy Study of a Urine DEK ELISA for Diagnosis of Bladder Cancer
The objective of this study is to use a DEK ELISA to quantitatively measure DEK protein in the urine of patients suspected of having bladder cancer.
- Conditions
- Hematuria, Dysuria, Bladder Cancer
- Trial name
- NCT01563796
- Where
- United States
- Volunteers
- 1,115 people
- Sponsor
- Medical Diagnostic Laboratories, LLC
Urothelial Cancer, Metastatic Urothelial Carcinoma
Sacituzumab Govitecan Plus EV in Metastatic UC
Phase I of this research study will assess what doses of Sacituzumab Govitecan and Enfortumab Vedotin can be safely combined in the treatment of metastatic urothelial carcinoma (mUC).
- Conditions
- Urothelial Cancer, Metastatic Urothelial Carcinoma, Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter, Bladder Cancer
- Trial name
- NCT04724018
- Testing
- Sacituzumab Govitecan (SG), Enfortumab vedotin-ejfv (EV), Pembrolizumab
- Where
- United States
- Volunteers
- 106 people
- Sponsor
- Dana-Farber Cancer Institute
Hematuria, Retention, Urinary
Anticoagulant/Antiaggregant Use and Postoperative Bleeding Risk in Patients With Bladder Tumor and Benign Prostatic Hyperplasia
Patients who were using anticoagulant or antiaggregant medications for any reason and underwent transurethral resection of bladder tumor (TUR-BT) or transurethral resection of the prostate (TURP) or open prostatectomy (OP) due to…
- Conditions
- Hematuria, Retention, Urinary, Operative Bleeding, Blood Transfusion Complication
- Trial name
- NCT05314582
- Where
- Turkey (Türkiye)
- Volunteers
- 500 people
- Sponsor
- Bezmialem Vakif University
Non-Muscle Invasive Bladder Cancer
Chemoablation Or Bladder Resection With Adjuvant Chemotherapy in Recurrent Non-Muscle Invasive Bladder Cancer
The investigartors will conduct a randomized, multinational study with the aim to assess if the efficacy of a dose dense chemoablation with Mitomycin C (MMC) with adjuvant BCG in non-responding patients is superior regarding long…
- Trial name
- COBRA-NMIBC (NCT06781879)
- Testing
- Mitomycin c
- Where
- 8 sites in Denmark, Iceland and 2 more
- Volunteers
- 272 people
- Sponsor
- Jakob Kristian Jakobsen
Cancer
Laboratory Assay in Determining Cancer Resistance in Patients With Metastatic Cancer and in Healthy Participants
RATIONALE: Studying samples of blood and tissue in the laboratory from patients with cancer and from healthy participants may help doctors learn more about cancer.
- Trial name
- NCT00899496
- Testing
- immunological diagnostic method, physiologic testing
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
Bladder Cancer, Prostate Cancer
Use of Multiphoton Microscopy in the Diagnosis of Cancer
Multiphoton microscopy (MPM) has been shown to be able to image tissue at a cellular level. Our project will initially evaluated the ability of MPM imaging to distinguish normal bladder urothelium from atypical and malignant…
- Trial name
- MPM (NCT00652210)
- Testing
- Multiphoton microscopy
- Where
- United States
- Volunteers
- 344 people, healthy volunteers welcome
- Sponsor
- Weill Medical College of Cornell University
Bladder Cancer
Evaluation of the Efficacy of Anti-HER2 Antibody-Drug Conjugates (ADC) in Locally Advanced or Metastatic Bladder Cancer Based on Organoid Technology.
This study, through a clinical controlled trial, compares the one-year, two-year, and three-year overall survival rates of patients in the treatment group guided by organoid drug sensitivity intervention with those of patients…
- Trial name
- NCT07379268
- Testing
- Organoid culture
- Where
- China
- Volunteers
- 224 people
- Sponsor
- Qilu Hospital of Shandong University
Muscle-Invasive Bladder Carcinoma, Tumor
Bladder Preservation for Patients With Muscle Invasive Bladder Cancer (MIBC) With Variant Histology
This is a Phase II, single cohort study designed to evaluate outcomes in patients with muscle invasive bladder cancer (MIBC) with variant histology who receive neoadjuvant chemotherapy (NAC) with or without immunotherapy (IO)…
- Trial name
- NCT06417190
- Testing
- Trimodal therapy (TMT) within 45 days of neoadjuvant chemotherapy (NAC)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Leslie Ballas
Bladder Cancer
A Novel Multiplex ELISA Assay for Evaluating Patients With Gross Hematuria for Bladder Cancer
To improve upon the non-invasive detection of BCa by further validating a multiplex ELISA assay directed at a BCa-associated diagnostic signature in voided urine samples of patients with gross hematuria.
- Trial name
- NCT03193528
- Where
- 6 sites in United States, Japan
- Volunteers
- 450 people
- Sponsor
- Cedars-Sinai Medical Center
Urinary Bladder Urothelial Carcinoma
Immunohistochemical Expression of CXCL5 as a Valuable Prognostic Marker in Urinary Bladder Urothelial Carcinoma
Urothelial carcinoma is common malignant tumor worldwide, it remains a challenge in the oncology field, it is an ideal for research on biomarkers that could identify tumor progression and prognosis.
- Trial name
- NCT05139134
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Sohag University
Bladder Papillary Urothelial Carcinoma, Stage 0a Bladder Urothelial Carcinoma
Ultrasound and Biomarker Tests in Predicting Cancer Aggressiveness in Tissue Samples of Patients With Bladder Cancer
This research trial studies two types of tests, an ultrasound test and a biomarker test, to see how well they predict how aggressive (invasive) bladder cancer is in samples from patients with bladder cancer.
- Conditions
- Bladder Papillary Urothelial Carcinoma, Stage 0a Bladder Urothelial Carcinoma, Stage 0is Bladder Urothelial Carcinoma, Stage I Bladder Cancer With Carcinoma In Situ
- Trial name
- NCT02494635
- Testing
- Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of Southern California
Bladder Cancer, Invasive Bladder Cancer
Nordic Cystectomy Study II - Albumin
Around 7200 cases of Muscle Invasive Bladder Cancer are diagnosed annually in the Nordic countries combined. Muscle Invasive Bladder Cancer is an aggressive disease and it is linked with high mortality rates.
- Trial name
- NorCys-Alb (NCT04523038)
- Testing
- S-Albumin
- Where
- Finland
- Volunteers
- 1,700 people
- Sponsor
- Turku University Hospital
Bladder Cancer
Microfluidic Urinary Exosome-Based Diagnostic Model for Bladder Cancer
Bladder cancer is one of the most common malignancies of the urinary system and is characterized by high recurrence rates and poor long-term outcomes.
- Trial name
- NCT07735858
- Testing
- Liquid biopsy
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Ovarian Cancer, Hepatocellular Carcinoma
Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors
This study will assess the safety and efficacy of DPX-Survivac and low dose cyclophosphamide with pembrolizumab in subjects with selected advanced and recurrent solid tumours.
- Conditions
- Ovarian Cancer, Hepatocellular Carcinoma, Non-small Cell Lung Cancer, Bladder Cancer
- Trial name
- NCT03836352
- Testing
- DPX-Survivac, Cyclophosphamide, Pembrolizumab
- Where
- 23 sites in United States, Canada
- Volunteers
- 184 people
- Sponsor
- ImmunoVaccine Technologies, Inc. (IMV Inc.)
Bladder (Urothelial, Transitional Cell) Cancer Metastatic or Unresectable, Upper Tract Urothelial Cancer
DDR Genes Alteration and Response to Platinum-based Chemotherapy in Advanced Urothelial Cancer.
This study aims to prospectively observe whether certain alterations in some genes related to the DNA repair mechanism are related to better response to platinum-based chemotherapy used to treat metastatic bladder or urothelial…
- Trial name
- SELECTIO-UC (NCT06820255)
- Testing
- Platinum + Gemcitabine, Avelumab first-line maintenance, NGS test for DDR alterations
- Where
- Italy
- Volunteers
- 135 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Solid Tumor, Adult, Bladder Cancer
Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid Tumors
This is an open-label pilot study of a new PET/CT imaging agent MNPR-101-DFO*-89Zr in patients with solid tumor cancers. These cancers may include bladder/urothelial, triple-negative breast, lung, colorectal, gastric, ovarian…
- Conditions
- Solid Tumor, Adult, Bladder Cancer, Urothelial Carcinoma, Triple-negative Breast Cancer
- Trial name
- NCT06337084
- Testing
- MNPR-101-DFO*-89Zr, PET/CT Diagnostic Imaging
- Where
- Australia
- Volunteers
- 12 people
- Sponsor
- Monopar Therapeutics
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.